These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 35655306)

  • 1. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine.
    Dhyani P; Quispe C; Sharma E; Bahukhandi A; Sati P; Attri DC; Szopa A; Sharifi-Rad J; Docea AO; Mardare I; Calina D; Cho WC
    Cancer Cell Int; 2022 Jun; 22(1):206. PubMed ID: 35655306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
    Pereira E; Tarasiuk J; Garnier-Suillerot A
    Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinca alkaloids.
    Moudi M; Go R; Yien CY; Nazre M
    Int J Prev Med; 2013 Nov; 4(11):1231-5. PubMed ID: 24404355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines.
    Mavrogiannis AV; Kokkinopoulou I; Kontos CK; Sideris DC
    Curr Pharm Biotechnol; 2018; 19(13):1076-1086. PubMed ID: 30417784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.
    Ren Y; DeRose K; Li L; Gallucci JC; Yu J; Douglas Kinghorn A
    Bioorg Med Chem; 2023 Sep; 92():117439. PubMed ID: 37579526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs.
    Kamata H; Sadahiro S; Yamori T
    Biol Pharm Bull; 2019 May; 42(5):814-818. PubMed ID: 30787205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
    Martino E; Casamassima G; Castiglione S; Cellupica E; Pantalone S; Papagni F; Rui M; Siciliano AM; Collina S
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2816-2826. PubMed ID: 30122223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkaloids for cancer prevention and therapy: Current progress and future perspectives.
    Mondal A; Gandhi A; Fimognari C; Atanasov AG; Bishayee A
    Eur J Pharmacol; 2019 Sep; 858():172472. PubMed ID: 31228447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental in vivo cross-resistance of vinca alkaloid drugs.
    Maral R; Bourut C; Chenu E; Mathe G
    Cancer Chemother Pharmacol; 1981; 5(3):197-9. PubMed ID: 7296754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
    Yau JC; Yap YY; Buzdar AU; Hortobagyi GN; Bodey GP; Blumenschein GR
    Cancer; 1985 Jan; 55(2):337-40. PubMed ID: 3880657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges.
    Banyal A; Tiwari S; Sharma A; Chanana I; Patel SKS; Kulshrestha S; Kumar P
    3 Biotech; 2023 Jun; 13(6):211. PubMed ID: 37251731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.
    Montag G; Stopper H; Ngo QA; Hintzsche H
    Curr Cancer Drug Targets; 2019; 19(3):222-230. PubMed ID: 29714145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catharanthus roseus (L.) G. Don: A review of its ethnobotany, phytochemistry, ethnopharmacology and toxicities.
    Kumar S; Singh B; Singh R
    J Ethnopharmacol; 2022 Feb; 284():114647. PubMed ID: 34562562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y; Yang SH; Guo XL
    Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery systems and combination therapy by using vinca alkaloids.
    Lee CT; Huang YW; Yang CH; Huang KS
    Curr Top Med Chem; 2015; 15(15):1491-500. PubMed ID: 25877096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies to antitumor Vinca alkaloids: thermodynamics and kinetics.
    Pontarotti PA; Rahmani R; Martin M; Barbet J
    Mol Immunol; 1985 Mar; 22(3):277-84. PubMed ID: 4000131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.